Alzamend Neuro, Inc.
ALZN$8M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaATLANTA
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Dec 15, 2026
33wMarket Overview
Stock performance and key metrics
ALZN News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
AL001
Alzheimer's Disease
ALZN002 (autologous DCs pulsed with E22W mutant peptide).
Alzheimer Disease
Lithium carbonate
Bipolar I Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AL001 | Phase 2 | Alzheimer's Disease | - | - |
ALZN002 (autologous DCs pulsed with E22W mutant peptide). | Phase 2 | Alzheimer Disease | - | - |
Lithium carbonate | Phase 2 | Bipolar I Disorder | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply